Videos

The professor of pediatric hematology/oncology at the University of Michigan Health also discussed open questions that remain for the future of the hemophilia B gene therapy.

The chairman of the Division of Pediatric Hematology & Oncology and BMT at Cleveland Clinic Children's discussed learnings from the institutions integration of gene therapy for sickle cell disease.

The professor of pediatric hematology/oncology at the University of Michigan Health discussed the final results of the phase 3 study that evaluated the hemophilia B gene therapy.

The chairman of the Division of Pediatric Hematology & Oncology and BMT at Cleveland Clinic Children's discussed results from the phase 1/2 RUBY trial he presented at ASH 2025.

The internal medicine resident at SUNY Upstate Medical University Hospital discussed findings from a patient population traditionally excluded from clinical trials for CAR-T.

The clinical fellow in hematology/oncology at the University of Pennsylvania discussed several sessions she's excited about at the ASH Annual Meeting.

The associate staff member at the Cleveland Clinic discussed the institution's experience with integrating use of exa-cel and lovo-cel.

The associate staff member at the Cleveland Clinic discussed a study he presented at ASH’s 2025 Annual Meeting.

In episode 7 of ImmunoLogic, Anusha Kalbasi, MD, discussed his research on the use of IL-9 to enhance CAR-T efficacy.

The genetic counselor in the Department of Ophthalmology at the University of Pittsburgh Medical Center discussed the growing role of genetic counselors in guiding patients undergoing gene therapy.

The vice president of Rare Disease Strategy at Worldwide Clinical Trials discussed the increasing importance of genetic counselors in clinical trials with regard to design, execution, and interpretation.

The president of the National Society of Genetic Counselors discussed AI and gene therapy, which constituted key topics at NSGC's annual conference this year.

The senior director of research and real world data at Genome Medical discussed multiple perspectives on how AI may take over some of the roles of genetic counselors in the future.

The senior director of research and real world data at Genome Medical discussed important considerations for genetic counselors thinking about using AI tools in their practice.

The senior director of research and real world data at Genome Medical discussed a session she chaired at the NSGC Annual Conference.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed how AI will affect cell and gene therapy research and practice.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on reducing costs for cell and gene therapy products.

The chief medical and development officer of Kyverna Therapeutics went over new data the company presented at AANEM’s 2025 meeting.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared their thoughts on the future of cell and gene therapy.

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, about the importance of big wins for cell and gene therapy research.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared advice for young scientists entering the cell and gene therapy field.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the unpredictability of "living drugs" in the human body and the ongoing development of understanding.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared their thoughts on how streamlined collaboration can help move therapies to patients faster.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed strategies used to streamline development in cell and gene therapy.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the major friction points in cell and gene therapy development and uptake.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed their thoughts on major moments in the past 25 years of cell and gene therapy research.

The cofounder of Child’s Cure Genetic Research discussed his daughter’s rare genetic disease and the need for new treatment options.

The director of the Mass General Brigham Gene and Cell Therapy Institute discussed a trend of doctors and scientists working on models to make gene therapy products financially viable.